Pulmonary fibrosis—also known in technical terms as idiopathic pulmonary fibrosis (IPF)—is a rare but life-threatening ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) with a progressive pulmonary fibrosis phenotype, ...

Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting the expression or function of Piezo2, a receptor that senses mechanical ...

Researchers at the University of Arizona have uncovered a previously unknown population of circulating immune cells that play ...

Last year, Houghton Hutcheson, now 79, started experiencing shortness of breath on a trip to Colorado. When he returned, he scheduled a visit with his primary care physician, Eric Thomas, MD, MPH, ...

Researchers at the University of Arizona uncovered a previously unknown population of circulating immune cells that play a ...

Insilico Medicine, a developer of artificial intelligence tools for drug discovery, has mapped out its process for making an experimental drug for idiopathic pulmonary fibrosis (IPF). In a paper ...

Pirfenidone, an oral antifibrotic, improves lung function and reduces acute pulmonary exacerbations in patients with grades 2-3 radiation induced lung injury.